SSO would like to thank the following companies for their support. Please select a name to learn more.
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.
The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients’ lives through science.
At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.
Elucent Medical has designed the EnVisio® Navigation System; a novel device that utilizes an innovative electromagnetic field and SmartClip® to enable precise stereotactic navigation within a wide field of view to a target of interest. The integration of the navigation tool onto the electrocautery device provides real-time guidance in the surgical field to deliver visual and audible indicators that provide Depth, Distance, and Direction to the SmartClip. This integrated system enables increased speed because of the ability to have the EM pad providing localization of SmartClips, in addition to the Real-Time Navigation is within the surgeon’s hand. The guidance and localization update as the tissue is manipulated during the surgery. The generation of an unprecedentedly large field of the electromagnetic field for navigation, the EnVisio System, and SmartClip technology broaden the treatable patient population expanding SmartClip localization from the breast, and lymph nodes to the head and neck, abdominal soft tissue as well as the lung in the future. Elucent Medical is founded on the continued collaboration of multi-disciplinary physicians who seek to improve patient outcomes. The EnVisio Navigation system addresses the clinical need to meet the broadest patient demographics from simple (single site) to complex (several sites in the breast and axilla) cases allowing individualized treatment.
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing non-opioid options to as many patients as possible to redefine the role of opioids as rescue therapy only. Pacira has three commercial-stage non-opioid options for treating pain: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesic approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, visit www.pacira.com.
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology pipeline spanning solid tumors and hematological cancers, including two late-stage clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. For more information, visit www.springworkstx.com and follow @SpringWorksTx on Twitter and LinkedIn.
Signatera is a personalized, tumor-informed, molecular residual disease test for patients previously diagnosed with cancer. Custom-built for each individual, Signatera uses circulating tumor DNA to detect and quantify cancer left in the body, identify recurrence earlier than standard of care tools, and help optimize treatment decisions. The test is available for clinical and research use and is covered by Medicare for patients with colorectal cancer, breast cancer (stage IIb and higher) and muscle invasive bladder cancer, as well as for immunotherapy monitoring of any solid tumor. Signatera has been clinically validated across multiple cancer types and indications, with published evidence in more than 60 peer-reviewed papers.
Castle Biosciences is a leading diagnostics company improving health through innovative tests that guide patient care. We aim to transform disease management by keeping patients and clinicians first. Our innovative tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions provide personalized, clinically actionable information to clinicians and patients to guide treatment decisions and improve health outcomes. (www.CastleBiosciences.com)
Additionally, we have active research and development programs for tests in other diseases with high clinical need, including our test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. Using our expertise in advanced technologies such as genomics, spatialomics and pharmacogenomics, data analytics and artificial intelligence, we dig deep into treatment pathways to develop clinically actionable tests that can improve the management of diseases and patient outcomes.
At Endomag, we believe everyone deserves a better standard of cancer care – that’s why we design our unique magnetic technologies with both the clinician and patient in mind. Many leading hospitals across the US use our solutions to help breast cancer patients avoid surgery when it isn’t needed, and experience better outcomes when it is.
How would you like to see a radiotracer move through the lymphatic nodal channel in real time? Or visually identify involved lymph nodes in real-time while in the operating room? (Even if the nodes are close to the primary injection site). Set your Geiger pen down and come visualize the future!
MD Anderson Cancer Center is recognized as a global leader for cutting-edge research, exceptional patient care, innovative prevention programs and our commitment to training the next generation of oncology experts.
MOLLI Surgical started with one patient’s voice — a patient who asked if there was a way to make her breast cancer journey better. Her voice led to the creation of our flagship wire and radiation-free technologies — MOLLI 2® and MOLLI re.markable™. Our innovations are intended to replace outdated procedures to mark lesions for surgical removal with greater precision, efficiency, and cost-effectiveness. We are obsessed with every detail of our design process to ensure surgeons and radiologists have the best possible tools in their hands to support an improved patient experience.
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools that address unmet medical needs. Based in Toronto, with U.S. headquarters in Dallas, Texas, Perimeter aims to harness the power of big data, artificial intelligence, and machine learning technology to further its mission of improving the standard of care, providing better long-term outcomes for patients, and reducing healthcare costs. Available now across the U.S., Perimeter’s S-Series OCT, powered by Optical Coherence Tomography, is designed to visualize tissues at the cellular level during surgical procedures, rather than days later when pathology reports come back. Our FDA-cleared technology gives surgeons cross-sectional visualization of surgical margins and excised tissues in real time, with 10x higher image resolution than standard X-ray and ultrasound, and 100x greater than MRI. Our next-generation technology will use ImgAssist AI, a powerful artificial intelligence and machine learning tool designed to assist surgeons with visualizing margins. In November 2021, Perimeter received FDA Investigational Device Exemption (IDE) approval and launched a multi-site, randomized clinical trial using Perimeter B-Series OCT with ImgAssist AI. The study evaluates this system against the current standard of care and assesses the impact on re-operation rates for patients undergoing breast conservation surgery. 
Merit Medical is dedicated to reducing the burden that cancer places on patients and their loved ones. Merit’s SCOUT® Radar Localization technology platform is the global leader in wire-free localization. Referenced in over 85 clinical publications, SCOUT is proven to reduce re-excision rates, streamline workflow and is the only localization device that can be placed at the time of biopsy or prior to neo-adjuvant chemotherapy with minimal MRI artifact and minimal migration. Merit recently received FDA clearance for SCOUT MD™, featuring unique reflector shapes and signals designed to revolutionize precision in tumor localization. Learn more at www.merit.com.
KUBTEC is challenging the status quo of breast cancer surgery and is committed to reducing the excessive number of re-excision surgeries. Through continuous research and development of our proprietary 3D tomosynthesis technology, KUBTEC is empowering surgeons with immediate visualization of surgical margins in the operating theater, helping to reduce re-excision rates, preserve healthy breast tissue, and ultimately improve patient outcomes. At KUBTEC we understand that one of the most important drivers of a positive outcome for breast cancer patients is ensuring clear margins at the time of surgery. This is what drives us to push the boundaries and work to set a new standard of care. Our proprietary award-winning technologies, such as 3D breast specimen tomosynthesis; advanced, high-resolution specimen X-ray imaging; and intelligent workflow management features are allowing us to do just that for every surgeon, radiologist, pathologist, pathologists’ assistant, and patient. For further information, please review our product line at https://kubtec.com/
Innoblative is a private medical device company addressing clinical unmet needs for patients with breast cancer and other soft tissue diseases. We are developing advanced energy-based surgical solutions to help improve the way surgeons coagulate and ablate soft tissue to achieve better care for patients. Innoblative has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the company’s SIRA® RFA Electrosurgical Device.
Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.
SkylineDx is a biotechnology company, focused on research & development of molecular diagnostics in oncology and inflammatory diseases. SkylineDx uses its expertise to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility, assisting healthcare professionals in accurately determining the type or status of disease or predict a patient’s response to treatment. Based on test results, healthcare professionals can tailor the treatment approach to the individual patient.
Curadel Surgical Innovations, Inc. (CSI) is the leading developer of contrast agents for Optical Surgical Navigation (OSN), also known as image-guided surgery or fluorescence-guided surgery. Our FLARE® brand of contrast agents (i.e., drugs) are engineered to work simultaneously at two different wavelengths (700 nm and 800 nm) thus providing oncologic surgeons with an unprecedented ability to see malignant cells that should be resected and normal tissues that need to be conserved. FLARE® drugs are injected intravenously at a low dose (1 to 5 mg) and highlight anatomic structures for hours. Our lead candidate is entering its pivotal trial and additional drug candidates are entering their commercialization phase.
Lumicell is focused on improving surgical outcomes by utilizing its innovative fluorescence-guided surgical system to remove residual cancer that may have otherwise been left behind. The investigational Lumicell Direct Visualization System is designed to detect residual cancerous tissue within the breast cavity during the initial lumpectomy procedure. Lumicell’s proprietary optical imaging agent, LUMISIGHT, is also being explored across a wide variety of solid tumor indications. For more information, please visit www.lumicell.com
Clarix Imaging’s mission is to empower clinicians with clear tumor visualization and intelligent analysis for precision and personalized medicine based on breakthrough innovations in imaging science and AI. Clarix Imaging offers the VSI-360™ System, a real-time 3D micro-CT intraoperative specimen imaging system providing the ability to evaluate the entire excisional volume at all 3 axial planes with much higher resolution and greater detail. Thus having the ability to look at any cross section of the specimen and visualize margins with higher confidence and unprecedented clarity.
Gunze is a leading medical device company headquartered in Japan. Gunze develops and manufactures a wide range of medical products focused on bioabsorbable and biocompatible materials such as tissue reinforcement felt, adhesion barriers, collagen-based wound matrix, bone fixation devices, dura substitutes, and suture thread. Gunze’s products provide comfort and relief post-surgery while enhancing regeneration and healing. With a substantial footprint in over 35 countries, our customers in healthcare have confidence in a proven, trusted brand that has been a source of innovative solutions.
Hackensack Meridian Health is the leading not-for-profit health care network in New Jersey offering a complete range of medical services, innovative research, and life-enhancing care aiming to serve as a national model for changing and simplifying health care delivery through partnerships with innovative companies and focusing on quality and safety.
Intera Oncology® Inc. is a Boston-based medical device company founded in 2019 by two doctors with a singular vision for improving the survival of patients with colorectal cancer and intrahepatic cholangiocarcinoma by ensuring access to Hepatic Artery Infusion (HAI) therapy. Dedicated to helping patients live longer and better lives by changing the course of cancer with HAI therapy, Intera Oncology manufactures the only FDA-approved pump for HAI therapy – the Intera 3000 Hepatic Artery Infusion Pump. Today, the treatment is used in more than 65 cancer centers across the U.S., including nine of the U.S. News & World Report’s top ten in the nation.
Piedmont Healthcare is a top-rated system with award winning hospitals and employees comprised of 23 hospitals and facilities, more than 3,500 physicians, and over 1600 clinic practice locations across greater Atlanta and North Georgia. With over 1 million outpatient encounters, you will have the opportunity to see and treat a variety of medical conditions. Piedmont Healthcare is a fast-growing, recognized leader in delivering expert care. Metro Atlanta’s vibrant economy fuels a wealth of global communities and diverse cultural experiences, while the state of Georgia offers coastline beaches and mountain views. Live and work with the best at Piedmont in the big and small towns of the Peach State.
SageMedic Corp, headquartered in California, is revolutionizing cancer diagnostics with a scalable platform that transcends the limitations of genomic testing, delivering results within just one week. Our pioneering Oncotest™ harnesses a machine learning enabled 3D live cell sensitivity and resistance assay, empowering oncologists to make informed treatment decisions for improved patient outcomes through functional tumor profiling.
Videra Surgical is an oncology surgery company focused on breast cancer treatment through the development and commercialization of a novel tumor bed marker called VeraForm®. Videra strongly believes that helping radiation oncologists better identify the tumor bed is essential for the continuum of care for breast cancer patients. VeraForm is an adaptable tissue marker comprised of a radiopaque filament that provides a continuous, 3-dimensional, multi-plane and permanent mark of a tumor bed. Taking a surgeon about 2-3 minutes to deploy, VeraForm is easily viewed by the radiation oncologist under X-ray and CT/CBCT, but it does not create artifact in MRI or ultrasound, as it is completely metal-free. VeraForm is 510(k) cleared and has been placed in thousands of patients in a rapidly growing number of U.S. centers. VeraForm is designed to provide a precise depiction of the tumor bed, allowing radiation oncologists to be more targeted in the delivery of radiation, in an attempt to avoid over-radiating and possibly damaging collateral tissue and organs.
XEOS is focused on improving outcomes in surgical oncology by leveraging the power of molecular imaging in the operating room. The company’s AURA 10 specimen PET-CT imager provides surgeons with an immediate 3-dimensional visualization of the resected tissue specimen at the point of surgery. This information helps the surgeon ensure that a complete resection is obtained.
INTUITIVE is a sponsor of the SSO 2024 Robotics Pre-Meeting- Advanced Robotic Surgery Workshop in Complex HPB/UGI.